- Home
- EXEL vs SUZ Comparison
EXEL vs SUZ Comparison
Compare EXEL & SUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | SUZ |
|---|---|---|
| Founded | 1994 | 1924 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 13.8B |
| IPO Year | 2000 | 2002 |
Fundamental Metrics
Financial Performance| Metric | EXEL | SUZ |
|---|---|---|
| Price | $41.26 | $10.02 |
| Analyst Decision | Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $46.45 | N/A |
| AVG Volume (30 Days) | 2.8M | ★ 3.2M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $452,477,000.00 | N/A |
| Revenue This Year | $13.66 | $13.61 |
| Revenue Next Year | $13.73 | $13.19 |
| P/E Ratio | $14.80 | ★ $5.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.38 | $8.41 |
| 52 Week High | $48.74 | $11.54 |
Technical Indicators
Market Signals| Indicator | EXEL | SUZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 38.47 |
| Support Level | $40.01 | $9.28 |
| Resistance Level | $44.15 | $10.04 |
| Average True Range (ATR) | 1.33 | 0.23 |
| MACD | -0.16 | -0.16 |
| Stochastic Oscillator | 26.06 | 1.30 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.